Table of Content

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview
Background: Genetic Material
RNA Interference Overview
RNA Interference: Mechanism of Action
Initiation Phase
Effector Phase
Small Interfering RNAs (siRNAs)
MicroRNAs (miRNAs)
Small Hairpin RNAs (shRNAs)

Chapter 3 Market Dynamics
Global Market Dynamics
Market Drivers
Increasing Prevalence of Chronic Disease
Increasing Approval of RNAi Products
Advancements in RNAi Delivery Systems
Increasing Strategic Initiatives
Convenient Dosing
Market Restraints
High Treatment Costs
Lack of Awareness
Market Opportunities
Expansion of Disease Targets
Combination Therapies
Untapped Genetic Targets

Chapter 4 Emerging Technologies and Developments
Therapeutics
Diagnostics
Circulating miRNA Diagnostics for Non-invasive Health Monitoring
Agriculture

Chapter 5 Pipeline Analysis

Chapter 6 Patent Analysis
Patent Analysis

Chapter 7 Market Segmentation Analysis
Segmentation Breakdown
Overview
Market Analysis by Technology
Therapeutics
RNAi Therapeutics Market, by Region
RNAi Therapeutics Market, by Therapeutic Area
RNAi Therapeutics Market, by Delivery Method
Diagnostics
Reagents and Tools
Agriculture
Geographic Breakdown
Market Analysis by Region
North America
Europe
Emerging Markets

Chapter 8 Competitive Intelligence
Strategic Initiatives
Competitive Analysis

Chapter 9 Sustainability in RNAi Technology Market: An ESG Perspective
Introduction to ESG
Sustainability in RNAi Technology Industry: An ESG Perspective
Environmental Initiatives
Social Initiatives
Governance Initiatives
Case Study

Chapter 10 Appendix
Methodology
Acronyms
Sources
Company Profiles
ALNYLAM PHARMACEUTICALS INC.
ARROWHEAD PHARMACEUTICALS INC.
ARBUTUS BIOPHARMA CORP.
BAYER AG
MERCK KGAA
NOVARTIS AG
NOVO NORDISK A/S
OLIX PHARMACEUTICALS INC.
QIAGEN
REVVITY INC.
SILENCE THERAPEUTICS
SIRNAOMICS
SYLENTIS S.A.
SWITCH THERAPEUTICS
THERMO FISHER SCIENTIFIC INC.



List of Figures

 

Summary Figure : Global Market for RNAi Technology, by Technology Type, 2021–2029
Figure 1 : RNAi Pathway
Figure 2 : Market Dynamics of RNAi Technology
Figure 3 : Tissues Targeted by RNAi Therapeutics
Figure 4 : Patents Documented Over Time, 2010–April 2024
Figure 5 : Global Market for RNAi Technology, by Technology Type, 2021–2029
Figure 6 : Global Market Shares of RNAi Technology, by Technology Type, 2023
Figure 7 : RNAi Therapeutics Timeline, 1998–2023
Figure 8 : Global Market for RNAi Therapeutics, by Region, 2021–2029
Figure 9 : Global Market for RNAi Therapeutics, by Therapeutic Area, 2021–2029
Figure 10 : Global Market for RNAi Therapeutics, by Delivery Method, 2021–2029
Figure 11 : MicroRNA (miRNA) Biomarkers in Various Cancers
Figure 12 : Global Market for RNAi Diagnostics, by Region, 2021–2029
Figure 13 : Global Market for RNAi Reagents and Tools, by Type, 2021–2029
Figure 14 : Global Market for RNAi Reagents and Tools, by Region, 2021–2029
Figure 15 : Global Market for RNAi Research Tools and Constructs, by Region, 2021–2029
Figure 16 : Global Market for RNAi Reagents, by Region, 2021–2029
Figure 17 : Global Market for RNAi Agriculture, by Region, 2021–2029
Figure 18 : Global Market for RNAi Technology, by Region, 2021–2029
Figure 19 : Global Market Shares of RNAi Technology, by Region, 2023
Figure 20 : Global Market Shares of RNAi Technology, by Suppliers/Manufacturers, 2023
Figure 21 : Research Communities’ Key Sustainable Practices in Research Laboratories
Figure 22 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
Figure 23 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
Figure 24 : Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 25 : Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 26 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 27 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 28 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 29 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 30 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2023
Figure 31 : Novo Nordisk A/S: Revenue Share, by Country/Region, FY 2023
Figure 32 : Qiagen: Revenue Share, by Business Unit, FY 2023
Figure 33 : Qiagen: Revenue Share, by Country/Region, FY 2023
Figure 34 : Revvity Inc.: Revenue Share, by Business Unit, FY 2023
Figure 35 : Revvity Inc.: Revenue Share, by Country/Region, FY 2023
Figure 36 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 37 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023

List of Tables


Summary Table : Global Market for RNAi Technology, by Technology Type, Through 2029
Table 1 : Projected Number of Adults 50 Years and Older with ?1 Chronic Condition in the U.S., 2020–2050
Table 2 : Cost Comparison of siRNA-approved Drugs and Alternative Therapies
Table 3 : List of Selected Pipeline Molecules
Table 4 : Selected Patents for RNAi Technology, Published in 2021
Table 5 : Selected Patents for RNAi Technology, Published in 2022
Table 6 : Selected Patents for RNAi Technology, Published in 2023
Table 7 : Selected Patents for RNAi Technology, Published January to April 2024
Table 8 : Global Market for RNAi Technology, by Technology Type, Through 2029
Table 9 : RNAi Approved Drugs List
Table 10 : Global Market for RNAi Therapeutics, by Region, Through 2029
Table 11 : Global Market for RNAi Therapeutics, by Therapeutic Area, Through 2029
Table 12 : Global Market for RNAi Therapeutics, by Delivery Method, Through 2029
Table 13 : miRNA-based Diagnostic Tools Available in Clinical Settings
Table 14 : Global Market for RNAi Diagnostics, by Region, Through 2029
Table 15 : Global Market for RNAi Reagents and Tools, by Type, Through 2029
Table 16 : Global Market for RNAi Reagents and Tools, by Region, Through 2029
Table 17 : Global Market for RNAi Research Tools and Constructs, by Region, Through 2029
Table 18 : Global Market for RNAi Reagents, by Region, Through 2029
Table 19 : Global Market for RNAi Agriculture, by Region, Through 2029
Table 20 : Global Market for RNAi Technology, by Region, Through 2029
Table 21 : Strategic Initiatives in Global RNAi Technology Market, 2020–2024
Table 22 : Global Rankings of Top RNAi Reagents and Tools Manufacturers, 2022
Table 23 : Key Focus Areas in ESG Metrices
Table 24 : Environmental Initiatives, by Various RNAi Technology Companies
Table 25 : ESG Rankings for Companies in the RNAi Technology Market, 2023
Table 26 : Alnylam’s ESG initiatives
Table 27 : Glossary of Terms Used in This Report
Table 28 : Report Information Sources
Table 29 : Alnylam Pharmaceuticals Inc.: Company Snapshot
Table 30 : Alnylam Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 31 : Alnylam Pharmaceuticals Inc.: Product Portfolio
Table 32 : Alnylam Pharmaceuticals Inc.: News/Key Developments, 2023
Table 33 : Arrowhead Pharmaceuticals Inc.: Company Snapshot
Table 34 : Arrowhead Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 35 : Arrowhead Pharmaceuticals Inc.: News/Key Developments, 2021-2024
Table 36 : Arbutus BioPharma Corp.: Company Snapshot
Table 37 : Arbutus Biopharma Corp.: Financial Performance, FY 2022 and 2023
Table 38 : Arbutus BioPharma Corp.: News/Key Developments, 2021-2023
Table 39 : Bayer AG: Company Snapshot
Table 40 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 41 : Bayer AG: Product Portfolio
Table 42 : Bayer AG: News/Key Developments, 2023
Table 43 : Merck KGaA: Company Snapshot
Table 44 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 45 : Merck KGaA.: Product Portfolio
Table 46 : Merck KGaA: News/Key Developments, 2021-2024
Table 47 : Novartis AG: Company Snapshot
Table 48 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 49 : Novartis AG: Product Portfolio
Table 50 : Novartis AG: News/Key Developments, 2020-2024
Table 51 : Novo Nordisk A/S: Company Snapshot
Table 52 : Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
Table 53 : Novo Nordisk A/S: Product Portfolio
Table 54 : Novo Nordisk A/S: News/Key Developments, 2021–2023
Table 55 : OliX Pharmaceuticals Inc.: Company Snapshot
Table 56 : OliX Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 57 : OliX Pharmaceuticals Inc.: News/Key Developments, 2019-2023
Table 58 : Qiagen: Company Snapshot
Table 59 : Qiagen: Financial Performance, FY 2022 and 2023
Table 60 : Qiagen: Product Portfolio
Table 61 : Qiagen: News/Key Developments, 2023
Table 62 : Revvity Inc.: Company Snapshot
Table 63 : Revvity Inc.: Financial Performance, FY 2022 and 2023
Table 64 : Revvity Inc.: Product Portfolio
Table 65 : Revvity Inc.: News/Key Developments, 2023 and 2024
Table 66 : Silence Therapeutics: Company Snapshot
Table 67 : Silence Therapeutics: Financial Performance, FY 2022 and 2023
Table 68 : Silence Therapeutics: News/Key Developments, 2022 and 2023
Table 69 : Sirnaomics: Company Snapshot
Table 70 : Sirnaomics: Financial Performance, FY 2022 and 2023
Table 71 : Sirnaomics: News/Key Developments, 2023
Table 72 : Sylentis S.A.: Company Snapshot
Table 73 : Sylentis S.A.: News/Key Developments, 2023
Table 74 : Switch Therapeutics: Company Snapshot
Table 75 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 76 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 77 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 78 : Thermo Fisher Scientific Inc.: News/Key Developments, 2021-2023